Cereno Scientific advances release of 2018 Annual Report and updates financial calendar

Cereno Scientific AB has resolved to update the company's financial calendar for 2019 as follows.

The annual report for 2018 will be published April 30, 2019 (previously scheduled for May 9, 2019).

Interim report for January – March 2019 will be published April 30, 2019 (previously scheduled May 23, 2019).

Annual General Meeting 2019: June 19 2019 in Gothenburg, Sweden (previously scheduled for June 11, 2019).

For further information, please contact:
Sten R. Sörensen – CEO
Tel: +46 733 74 03 74
E-mail: sten.sorensen@cerenoscientific.com
www.cerenoscientific.se

About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.